- Mechanism
- Binds cardiolipin to stabilize inner mitochondrial membrane
- Typical research dose
- 40-60 mg/day subcutaneous (clinical trials)
- Route
- subcutaneous
- Half-life
- ~2 hours
- Legal status
- Investigational / Clinical Trials
Overview
The SS-31 (Elamipretide) peptide is a synthetic, cell-permeable compound engineered to target and protect the inner mitochondrial membrane. By selectively binding to cardiolipin, it stabilizes mitochondrial structure, optimizes the electron transport chain, and mitigates oxidative stress at its cellular source. Researchers are actively investigating its potential to treat highly metabolic conditions, including age-related macular degeneration, acute kidney injury, and primary mitochondrial myopathies.
Potential Benefits
- Mitochondrial Stabilization: Binds directly to cardiolipin to restore inner mitochondrial membrane integrity and improve ATP production.
- Ocular Protection: Shows promise as a therapeutic candidate for age-related macular degeneration (AMD) by reducing retinal oxidative damage (Nashine S, 2021).
- Kidney Injury Mitigation: Investigated for its ability to protect renal tissue during acute kidney injury by preserving mitochondrial function (Patel PS et al., 2026).
- Dry AMD Treatment: Emerging technologies highlight its potential as an innovative therapeutic perspective for dry AMD (Ciszewski P et al., 2025).
- Friedreich's Ataxia Support: Evaluated in clinical trials for improving mitochondrial dysfunction associated with Friedreich's Ataxia (ClinicalTrials.gov, NCT05168774).
- Reduced Oxidative Stress: Decreases the pathological generation of reactive oxygen species without interfering with normal cellular signaling.
Where to Buy SS-31 (Elamipretide)
Research compound. SS-31 (Elamipretide) is a research chemical, typically not FDA-approved for human consumption. Sale or use for human consumption may be illegal in your jurisdiction.
No compensation. PeptideStack does not endorse, verify, or receive compensation from any vendor. No affiliate or referral relationships.
Verify third-party COAs and consult a qualified healthcare provider before using any compound.
Side Effects
Common side effects:
- Injection site erythema or redness
- Mild localized pruritus (itching)
- Temporary injection site swelling
- Mild headache
- Dizziness or lightheadedness
Rare or serious side effects:
- Hypersensitivity or allergic reactions
- Unexplained fatigue or lethargy
- Changes in blood pressure
- Gastrointestinal distress
SS-31 (Elamipretide) is not FDA-approved and is intended for research purposes only. Consult a qualified healthcare provider before use.
Mechanism of Action
Mitochondrial targeting defines the primary mechanism of the SS-31 (Elamipretide) peptide, as it selectively penetrates cell membranes to reach the inner mitochondrial membrane (IMM). Once inside, it binds electrostatically and hydrophobically to cardiolipin, a unique phospholipid crucial for IMM curvature and protein complex stability. This interaction prevents cytochrome c peroxidase activity, ensuring that cytochrome c remains an electron carrier rather than a generator of reactive oxygen species.
Cellular energy restoration occurs as a direct result of this structural stabilization. By optimizing the electron transport chain, SS-31 enhances ATP synthesis while simultaneously reducing pathological oxidative stress. This dual action preserves cellular viability in highly metabolic tissues, such as the retina and kidneys, particularly under ischemic or toxic conditions.
Origin & History
Synthetic development of SS-31 (Elamipretide) originated from research into Szeto-Schiller (SS) peptides, a novel class of compounds engineered for targeted mitochondrial delivery. Initially synthesized to combat oxidative stress, the peptide quickly demonstrated unique cardiolipin-binding properties that distinguished it from traditional antioxidants. Early preclinical success propelled the compound, also known as Bendavia, into extensive research for age-related and metabolic conditions.
Clinical trial progression has marked the regulatory journey of this peptide, though it currently remains an investigational drug without full FDA approval. It has been evaluated in multiple human studies, including completed Phase 2 trials for Friedreich's Ataxia (ClinicalTrials.gov, NCT05168774). Ongoing research continues to assess SS-31 (Elamipretide) benefits and safety profiles for various mitochondrial myopathies and ophthalmic diseases.